Clinical Trial Readiness for Functional Neurological Disorders (U01 Clinical Trial Optional)
ID: 336363Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/336363

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-22-053.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity for research aimed at enhancing Clinical Trial Readiness for Functional Neurological Disorders (FNDs) through a cooperative agreement. This initiative seeks prospective clinical projects that focus on validating biomarkers and clinical outcome assessments (COAs) to improve the diagnosis and management of FNDs, which present significant challenges due to their complex neurological and psychiatric symptoms. The funding is critical in addressing the healthcare crisis posed by FNDs, facilitating collaborations among researchers, industry, and patient advocacy groups to optimize therapeutic interventions. Interested applicants must submit their proposals by November 5, 2024, and can find additional information and application guidelines at the NIH website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    PAR-22-053-Full-Announcement.html
    PAR-22-053.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and specifically the National Institute of Neurological Disorders and Stroke (NINDS), has issued a funding opportunity for research focused on Clinical Trial Readiness for Functional Neurological Disorders (FNDs). This initiative emphasizes the need for prospective clinical projects that establish valid biomarkers and clinical outcome assessments (COAs) for FNDs, which are complex conditions characterized by significant neurological and psychiatric symptoms. The funding aims to facilitate partnerships among researchers, industry, and patient advocacy groups to enhance the clarity of diagnostic criteria and treatment responses through rigorous clinical trials. Key dates for application submissions span from February 2022 to November 2024, with the potential for multiple awards based on meritorious applications. The application process is facilitated through NIH’s ASSIST system with strict adherence to specified guidelines. Collaborative efforts in study design and execution are encouraged, along with a multi-disciplinary approach involving experts in clinical care, laboratory analysis, and statistical validation. The initiative stands to fill a critical gap in addressing the healthcare crisis posed by FNDs, leveraging optimized clinical measures to improve therapeutic interventions and patient care.
    Similar Opportunities
    Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the clinical validation of candidate biomarkers for neurological and neuromuscular disorders through the U44 Cooperative Agreement mechanism. This initiative aims to rigorously validate biomarkers that have already been identified and for which detection methods have been developed, ensuring compliance with FDA guidelines to establish their clinical sensitivity and specificity. This program is crucial for advancing therapeutic development in the field of brain health, with funding potentially reaching $700,000 for Phase I and $1.5 million for Phase II projects. Interested applicants must adhere to specific submission guidelines and deadlines, with the application closing on June 22, 2026. For further information, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-096.html.
    Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)" under Funding Opportunity Number PAR-24-097. This initiative aims to clinically validate candidate biomarkers for neurological diseases, focusing on establishing their clinical sensitivity and specificity, provided that preliminary conditions such as detection method development are met. The program emphasizes the importance of multidisciplinary collaborations and requires applicants to include a Plan for Enhancing Diverse Perspectives (PEDP) to promote inclusivity in research teams. Interested applicants must submit their proposals by February 22, 2024, with project durations capped at five years. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-097.html.
    Development of Biomarkers or Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Development of Biomarkers or Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)." This initiative aims to promote the discovery and early evaluation of candidate biomarkers that can facilitate the clinical development of neurotherapeutics and their application in clinical practice, focusing on both animal studies and preliminary human evaluations. The funding is structured as a phased R61/R33 award, where the R61 phase emphasizes proof-of-concept studies using human samples, while the R33 phase focuses on clinical validation for specified uses. Interested applicants, including various educational and community organizations, must submit their proposals by May 7, 2025, and can find additional details and application guidelines at the provided NIH link. For inquiries, applicants can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    NINDS Exploratory Clinical Trials (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Neurological Disorders and Stroke (NINDS), is offering a funding opportunity for investigator-initiated exploratory clinical trials under the UG3/UH3 mechanism. This initiative aims to support Phase 1 and Phase 2 clinical trials that address critical questions related to neurological disorders, focusing on studies involving drugs, biologics, devices, and early interventions. The program emphasizes rigorous research design and encourages diverse and innovative research teams, with grants potentially spanning up to five years, beginning with a planning phase before transitioning to execution. Interested applicants can find more information and application details at the provided link, with a submission deadline of March 10, 2025, and no cost-sharing or matching requirement.
    Notice of Intent to Publish a Funding Opportunity Announcement for Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for research focused on the neurological effects of infection-associated chronic illnesses, including conditions like Neuro-PASC, post-treatment Lyme Disease, and ME/CFS. This initiative aims to promote understanding of the neuropsychiatric manifestations of these illnesses, with a particular interest in projects that explore common mechanisms across multiple conditions, although applications can focus on individual illnesses as well. The anticipated funding amount for this grant is up to $500,000, with the NOFO expected to be published in Fall 2024 and applications due in Winter 2025. Interested applicants should prepare to submit their proposals by the estimated closing date of February 3, 2025, with awards expected to be made by December 1, 2025.
    NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for investigator-initiated efficacy clinical trials through the NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required) program. This initiative aims to support clinical studies that evaluate drugs, biologics, devices, and various interventions targeting neurological disorders, requiring a phased approach where UG3 planning must precede UH3 execution. The trials must be well-designed with robust scientific rationale and diverse participant inclusion, emphasizing collaboration with patient advocacy groups and national networks. Interested applicants can find more information and application guidelines at the provided NIH link, with a submission deadline of January 9, 2025, and no cost-sharing or matching requirements. For inquiries, contact the NIH OER Webmaster at grantsinfo@nih.gov.
    Notice of Intent to Publish a Funding Opportunity Announcement for Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R21 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at enhancing the understanding of the neurological effects associated with infection-related chronic illnesses, including conditions like Neuro-PASC, post-treatment Lyme Disease, and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). This initiative encourages research projects that explore the neurological and psychiatric manifestations of these illnesses, with a particular interest in studies that may identify common neuropsychiatric mechanisms across multiple conditions, although applications focusing on individual illnesses are also welcome. The NOFO is anticipated to be released in Fall 2024, with applications due in Winter 2025, and will utilize the R21 grant mechanism. Interested applicants should prepare for a project start date expected in December 2025, with further details to be outlined in the forthcoming announcement.
    Global Brain and Nervous System Disorders Research Across the Lifespan (R01 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the "Global Brain and Nervous System Disorders Research Across the Lifespan (R01 Clinical Trials Optional)" grant, aimed at fostering innovative research collaborations between U.S. institutions and scientists in low- and middle-income countries (LMICs). This initiative seeks to address a range of neurological, mental, and behavioral disorders by encouraging partnerships that enhance research capacity and develop culturally sensitive interventions tailored to the unique challenges faced by these regions. The program emphasizes the importance of addressing socioeconomic factors impacting health outcomes and aims to build sustainable research frameworks to tackle neuro-health issues across the lifespan. Interested applicants must submit their proposals by December 9, 2024, and can find additional information and application guidelines at the NIH grants website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed) grant. This funding opportunity aims to support projects that address critical needs for clinical trial readiness in rare diseases, specifically by facilitating the development of biomarkers and clinical outcome measures essential for trial design. The initiative is particularly important for advancing research on diseases affecting fewer than 200,000 individuals in the U.S., enhancing the likelihood of successful clinical trials. Applicants can request up to $275,000 over two years, with a submission deadline of October 17, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-159.html.
    Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders(U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through a Cooperative Agreement for the analytical validation of candidate biomarkers aimed at neurological and neuromuscular disorders. This initiative seeks to rigorously validate analytical methods for biomarker measurements, ensuring their accuracy and reproducibility in alignment with FDA guidelines, with a focus on addressing unmet clinical needs and potential applications in clinical trials. The program encourages diverse research teams and collaboration, emphasizing the importance of inclusivity in the research process, and applications are due by June 22, 2026, with funding available for a maximum period of four years. Interested applicants can find more information and guidelines at the NIH Grants website or contact NIH Grants Information at grantsinfo@nih.gov.